Escherichia coli hns and methylglyoxal link gut microbial metabolism to host neuronal gene regulation in Parkinson's disease.

The bacterial gene hns, primarily derived from E. coli, was enriched in body-first Parkinson's disease compared to other PD subtypes in a stool metagenomic cohort.

• hns encodes the histone-like nucleoid structuring protein in E. coli
• Body-first PD is a subtype associated with gut-originating pathology, making this enrichment mechanistically relevant
• The enrichment was identified through stool metagenomic sequencing of a PD patient cohort
• hns was identified as primarily E. coli-derived in the metagenomic data

Plasma levels of methylglyoxal (MG) were higher in body-first PD than in brain-first PD and were nominally inversely associated with cardiac MIBG uptake within the body-first group.

• MG is a reactive metabolite whose bacterial production was shown to be hns-dependent in the model system
• The association with cardiac meta-iodobenzylguanidine (MIBG) uptake was described as 'nominally' inversely associated, indicating a trend-level finding within the body-first subgroup
• Cardiac MIBG uptake is a measure of sympathetic cardiac innervation relevant to PD pathology
• Data were obtained from a separate plasma MG cohort distinct from the metagenomic cohort

Feeding C. elegans PD models with Δhns E. coli (hns-deletion mutant) protected dopaminergic neurons compared to wild-type E. coli.

• C. elegans were used as PD models for in vivo assessment of dopaminergic neuroprotection
• The deletion of hns in E. coli (Δhns) was sufficient to confer neuroprotection to host dopaminergic neurons
• This finding established a causal link between the bacterial hns gene and host neuronal outcomes
• The model used feeding as the route of bacterial exposure, mimicking gut microbiota interaction

Exogenous methylglyoxal abolished the neuroprotection conferred by Δhns E. coli in C. elegans PD models.

• MG was added exogenously to C. elegans fed Δhns E. coli, reversing the neuroprotective effect
• This finding places MG downstream of hns as the mechanistic mediator of dopaminergic vulnerability
• Bacterial MG production was shown to be hns-dependent in the model system
• The rescue experiment with exogenous MG provided causal evidence that MG is the key metabolite linking hns to neuronal outcomes

Transcriptomic and neuronal RNAi analyses identified rig-5 as the host C. elegans mediator of hns deletion-induced neuroprotection.

• Transcriptomic analysis was performed to identify host gene expression changes induced by Δhns E. coli feeding
• Neuronal RNAi was used to functionally validate rig-5 as necessary for the neuroprotective effect
• rig-5 is a C. elegans gene whose expression was modulated by the bacterial hns-MG pathway
• This identified a specific host gene target downstream of the microbial metabolite pathway

Cross-species analyses identified LSAMP (Limbic System-Associated Membrane Protein) as a candidate mammalian ortholog of C. elegans rig-5.

• LSAMP was identified through cross-species comparative genomic/transcriptomic analysis
• LSAMP is expressed in the limbic system and associated membrane structures in mammals
• The ortholog relationship between rig-5 and LSAMP extended the C. elegans findings to mammalian relevance
• This cross-species approach connected invertebrate model findings to human disease biology

Methylglyoxal suppressed LSAMP expression in human neuronal cells.

• Exogenous MG treatment of human neuronal cells in vitro reduced LSAMP expression
• This finding translated the C. elegans rig-5 findings to a human cellular system
• The result supported MG as a direct suppressor of the rig-5/LSAMP neuroprotective pathway in human neurons
• Human neuronal cells were used as the model system for this in vitro experiment

LSAMP expression was reduced in the post-mortem substantia nigra of patients with Parkinson's disease.

• Post-mortem human brain tissue from the substantia nigra (SN) was analyzed for LSAMP expression
• The SN is the primary brain region affected by dopaminergic neuron loss in PD
• Reduced LSAMP in PD patient SN is consistent with the proposed hns-MG-LSAMP suppressive pathway
• This finding provided human disease-relevant evidence supporting the pathway's clinical significance

Lsamp expression was increased in the substantia nigra of mice colonized with Δhns E. coli compared to wild-type E. coli.

• Germ-free or conventionally housed mice were colonized with either Δhns or wild-type E. coli
• SN tissue was analyzed for Lsamp expression, showing upregulation in the Δhns-colonized group
• This in vivo mammalian experiment confirmed that gut bacterial hns status influences brain LSAMP expression
• The finding in mice complemented and validated the mechanistic pathway identified in C. elegans and human cell studies

The study delineates a complete microbial gene-metabolite-host gene pathway: E. coli hns → methylglyoxal production → suppression of rig-5/LSAMP → dopaminergic vulnerability.

• The pathway connects a specific bacterial gene (hns) through a defined metabolite (MG) to host neuronal gene regulation (rig-5/LSAMP)
• Evidence spans multiple model systems: stool metagenomics in humans, plasma metabolomics in humans, C. elegans in vivo, human neuronal cells in vitro, post-mortem human brain tissue, and mouse colonization experiments
• The pathway is particularly relevant to body-first PD, a subtype with presumed gut-originating pathology
• This represents one of the first studies to link a specific bacterial gene to defined host neuronal gene regulation in PD